1. Reconciled Oncology and Hematology Execution & Stop-Cause Profile
| Clinical Trial Metric | Verified Value | Operational Context |
|---|---|---|
| Total Phase II & III Protocols (2018 to 2026) | 22,601 | Deterministic primary MeSH and condition-keyword assignment |
| Active Concurrent Pipeline | 12,884 | Recruiting, enrolling by invitation, and active follow-up protocols |
| Completed vs Prematurely Stopped | 3,040 / 2,734 | 47.35% closed-trial attrition ratio across 5,774 closed protocols |
| Slow Accrual vs Safety & Futility Stops | 746 / 280 / 126 | Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5) |
| Physical Hospital Site Disclosure Rate | 89.7% | Named hospital campus participations vs anonymized CRO site slots |
2. Leading Consolidated Trial Sponsors Focused on Oncology and Hematology
| Sponsor Hub | Sector | Protocols | Active | Completed | FDA NDA/BLA |
|---|---|---|---|---|---|
| Sun Yat-sen University | Academic / Institutional Sponsor | 665 | 365 | 60 | 0 |
| Fudan University | Academic / Institutional Sponsor | 571 | 352 | 31 | 0 |
| AstraZeneca | Biopharma Industry | 534 | 300 | 175 | 81 |
| MD Anderson Cancer Center | Academic / Cooperative Group | 519 | 344 | 38 | 0 |
| Novartis | Biopharma Industry | 492 | 179 | 194 | 224 |
| National Cancer Institute (NCI) | Federal / NIH | 458 | 318 | 52 | 0 |
| Merck & Co. | Biopharma Industry | 439 | 201 | 195 | 183 |
| Pfizer | Biopharma Industry | 377 | 143 | 161 | 418 |
| Roche / Genentech | Biopharma Industry | 353 | 158 | 131 | 95 |
| Memorial Sloan Kettering Cancer Center | Academic / Cooperative Group | 308 | 236 | 44 | 0 |
| Johnson & Johnson / Janssen | Biopharma Industry | 300 | 122 | 123 | 131 |
| Tianjin Medical University Cancer Institute and Hospital | Academic / Institutional Sponsor | 273 | 158 | 11 | 0 |
3. Representative Multi-Center Phase II & III Oncology and Hematology Studies
| NCT Study | Protocol Brief Title | Sponsor | Phase | Status |
|---|---|---|---|---|
| NCT05646316 | Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer | NRG Oncology | Phase III | RECRUITING |
| NCT05886036 | Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial | National Cancer Institute (NCI) | Phase II | RECRUITING |
| NCT06661915 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | National Cancer Institute (NCI) | Phase II | RECRUITING |
| NCT05657873 | A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) | Memorial Sloan Kettering Cancer Center | Phase II | RECRUITING |
| NCT07111507 | A Study of Tarlatamab for People With Prostate Cancer | Memorial Sloan Kettering Cancer Center | Phase II | RECRUITING |
| NCT05848765 | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | University of Birmingham | Phase II | RECRUITING |
| NCT05751434 | A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer | City of Hope | Phase II | RECRUITING |
| NCT05188508 | Pembrolizumab, Olaparib, and Temozolomide for People With Glioma | Memorial Sloan Kettering Cancer Center | Phase II | RECRUITING |
| NCT06451861 | Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | Guangdong Provincial People's Hospital | Phase II | RECRUITING |
| NCT06882057 | Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol | Institute of Hematology & Blood Diseases Hospital, China | Phase II/III | RECRUITING |
| NCT06855810 | Newly-diagnosed Pediatric T-cell ALL Protocol | Institute of Hematology & Blood Diseases Hospital, China | Phase II/III | RECRUITING |
| NCT06764238 | Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol | Institute of Hematology & Blood Diseases Hospital, China | Phase II/III | RECRUITING |
| NCT05806931 | Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer | Rutgers, The State University of New Jersey | Phase II | RECRUITING |
| NCT05559164 | Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted | Rutgers, The State University of New Jersey | Phase II | RECRUITING |
| NCT07450599 | A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. | Bayer | Phase II | RECRUITING |
| NCT05011383 | High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers | VA Office of Research and Development | Phase II | RECRUITING |
Related Therapeutic Condition Hubs & Crosswalks
Compare adjacent clinical cohorts: Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain · Immunology, Rheumatology, and Dermatology, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.